Copanlisib Disease Interactions
There are 5 disease interactions with copanlisib.
Copanlisib (applies to copanlisib) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Copanlisib is primarily metabolize by the liver. Based on the population pharmacokinetic analysis, no clinically relevant difference was observed in patients with mild hepatic impairment. The pharmacokinetics of copanlisib have not been evaluated in patients with moderate to severe hepatic impairment. Close monitoring is recommended in these patients.
Copanlisib (applies to copanlisib) hyperglycemia
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus
Hyperglycemia has occurred in patients treated with copanlisib. Before starting copanlisib patients should achieve optimal blood glucose control and dose should be reduced, or therapy temporarily discontinued depending on the severity and persistent of hyperglycemia. Diabetic patients should only be treated with this agent following adequate glucose control and should be monitored closely.
Copanlisib (applies to copanlisib) hypertension
Moderate Potential Hazard, Moderate plausibility.
Hypertension has occurred in patients treated with copanlisib. Before starting copanlisib patients should achieve optimal blood pressure control and dose should be reduced, or therapy temporarily discontinued depending on the severity and persistence of hypertension. It is recommended to monitor blood pressure before and after the infusion with copanlisib.
Copanlisib (applies to copanlisib) infections
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral, Immunodeficiency, Bone Marrow Depression/Low Blood Counts, Interstitial Pneumonitis
Serious infections, including infections and non-infectious pneumonitis, have occurred in patients treated with copanlisib. Care should be exercised in patients at risk as in those at increased susceptibility to infection, such as neutropenic patients or those with a prior history of jiroveci pneumonia infection. It is recommended to monitor patients closely according to medical practice and for signs and symptoms of infection and to treat as medically appropriate. The dose should be reduced, or therapy temporarily discontinued depending on the severity and persistence of symptoms.
Copanlisib (applies to copanlisib) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Copanlisib undergoes minimal renal elimination. Based on the population pharmacokinetic analysis, no clinically relevant difference was observed in patients with mild or moderate renal impairment. The pharmacokinetic copanlisib has not been evaluated in patients with severe renal impairment or in those patients with end stage renal disease with or without dialysis. Close monitoring is recommended in these patients.
Switch to professional interaction data
Copanlisib drug interactions
There are 340 drug interactions with copanlisib.
Copanlisib alcohol/food interactions
There are 2 alcohol/food interactions with copanlisib.
Report options
More about copanlisib
- copanlisib consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: PI3K inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.